Jason Assad - 180 Life Director IR
| ATNF Stock | USD 2.25 0.03 1.32% |
Insider
Jason Assad is Director IR of 180 Life Sciences
| Address | Building 4, Palo Alto, CA, United States, 94306 |
| Phone | 650 507 0669 |
| Web | https://180lifesciences.com |
180 Life Management Efficiency
The company has return on total asset (ROA) of (0.635) % which means that it has lost $0.635 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.9858) %, meaning that it created substantial loss on money invested by shareholders. 180 Life's management efficiency ratios could be used to measure how well 180 Life manages its routine affairs as well as how well it operates its assets and liabilities. The 180 Life's current Return On Equity is estimated to increase to 163.87, while Return On Tangible Assets are projected to decrease to (5.75). At this time, 180 Life's Net Tangible Assets are most likely to increase significantly in the upcoming years. The 180 Life's current Debt To Assets is estimated to increase to 0.21, while Non Current Assets Total are projected to decrease to roughly 1.5 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Pablo MD | ZyVersa Therapeutics | N/A | |
| DSc MSE | Immix Biopharma | 75 | |
| JD MBA | Immix Biopharma | N/A | |
| CPA CTP | Cns Pharmaceuticals | 44 | |
| LaBella MS | ZyVersa Therapeutics | 66 | |
| Karen Cashmere | ZyVersa Therapeutics | 72 | |
| Timur Dogan | Cardio Diagnostics Holdings | 36 | |
| Avani Kanubaddi | Enveric Biosciences | 51 | |
| Samuel MD | Altamira Therapeutics | 71 | |
| Manuel Dafonseca | Sonnet Biotherapeutics Holdings | N/A | |
| Dr MedSc | Phio Pharmaceuticals Corp | 68 | |
| Waldemar Priebe | Cns Pharmaceuticals | N/A | |
| Gabriel BA | Immix Biopharma | 37 | |
| Sharon McBrayer | Palisade Bio | N/A | |
| Marcel CPA | Altamira Therapeutics | 66 | |
| MBA IV | Enveric Biosciences | 68 | |
| Nandan BS | Immix Biopharma | 62 | |
| Ibrahim MD | Enveric Biosciences | 55 | |
| Robert McRae | Palisade Bio | N/A | |
| John Cini | Sonnet Biotherapeutics Holdings | 71 | |
| MD FACP | Sonnet Biotherapeutics Holdings | 66 | |
Management Performance
| Return On Equity | -3.99 | ||||
| Return On Asset | -0.63 |
180 Life Sciences Leadership Team
Elected by the shareholders, the 180 Life's board of directors comprises two types of representatives: 180 Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of 180. The board's role is to monitor 180 Life's management team and ensure that shareholders' interests are well served. 180 Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, 180 Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sir Feldmann, CoFounder CoChairman | ||
| CPA CPCU, CFO Director | ||
| Quan Vu, COO Officer | ||
| BA MD, CoFounder CoChairman | ||
| Raphael Mechoulam, CoFounder Board | ||
| Jason Assad, Director IR | ||
| Pr Nanchahal, CoFounder Board | ||
| MBA LLB, Interim Director | ||
| Ozan CFA, CFO Secretary | ||
| Pr MD, CoFounder Board | ||
| Jonathan Rothbard, Chief Officer |
180 Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is 180 Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.99 | ||||
| Return On Asset | -0.63 | ||||
| Current Valuation | 7.57 M | ||||
| Shares Outstanding | 1.98 M | ||||
| Shares Owned By Insiders | 4.34 % | ||||
| Shares Owned By Institutions | 3.45 % | ||||
| Number Of Shares Shorted | 139.43 K | ||||
| Price To Earning | 0.63 X | ||||
| Price To Book | 1.21 X | ||||
| EBITDA | (22.13 M) |
Currently Active Assets on Macroaxis
When determining whether 180 Life Sciences is a strong investment it is important to analyze 180 Life's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact 180 Life's future performance. For an informed investment choice regarding 180 Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in 180 Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 180 Life. If investors know 180 will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 180 Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 7.98 | Return On Assets (0.64) | Return On Equity (3.99) |
The market value of 180 Life Sciences is measured differently than its book value, which is the value of 180 that is recorded on the company's balance sheet. Investors also form their own opinion of 180 Life's value that differs from its market value or its book value, called intrinsic value, which is 180 Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 180 Life's market value can be influenced by many factors that don't directly affect 180 Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 180 Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if 180 Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 180 Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.